Table 3.

Univariate log-rank analysis for important clinicopathological variables and DUOX2 expression

Parameter		No. of case	Disease-specific survival		Local recurrence-free survival			Metastasis-free survival
			No. of event	P	No. of event	P		No. of event	P
Gender	Male	108	20	0.9026	7	0.2250		17	0.3520
	Female	64	11		20			14
Age	<70	106	19	0.8540	18	0.6615		20	0.7427
	≥70	66	12		9			11
Pre-CCRT cT stage	cT1-2	81	10	0.0776	10	0.2261		11	0.1745
	cT3-4	91	21		17			20
Pre-CCRT cN stage	cN0	125	19	0.0711	15	0.0070*		19	0.0973
	cN1-2	47	21		12			12
Pre-CCRT CEA	≤5 ng/ml	114	15	0.0216*	13	0.0179*		17	0.1460
	>5 ng/ml	58	16		14			14
Post-CCRT pT stage	ypT0-2	86	7	0.0006*	7	0.0040*		8	0.0033*
	ypT3-4	86	24		20			23
Post-CCRT pN stage	ypN0	123	21	0.5998	16	0.1320		20	0.4634
	ypN1-2	49	10		11			11
Lymphovascular invasion	Absent	157	25	0.0184*	21	0.0028*		27	0.4470
	Present	15	6		6			4
Perineural invasion	Absent	167	29	0.2559	25	0.0940		30	0.9083
	Present	5	2		2			1
Tumor regression grade	Grade 0-1	37	13	0.0038*	10	0.0090*		14	0.0006*
	Grade 2-3	118	17		17			16
	Grade 4	17	1		0			1
DUOX2 expression	Low Exp.	86	6	<0.0001*	4	<0.0001*	9		0.0097*
	High Exp.	86	25		23		22

*, statistically significant